ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0523

SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement

Jennifer Soung1, Virginie Kelly2, Marni Wiseman3, Adrian Rodriguez4, Theodore Alkousakis5, Olivia Choi5, Daphne Chan5, Katelyn Rowland5, Linda Hou6, Jenny Jeyarajah7, Nastaran Abbarin8, Elizabeth Skobelev5, Sancharitha Ramji5, James Krell9, Max Sauder10 and David Adam11, 1Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, 2Saint-Louis Medical Clinic, Quebec, Canada, Quebec, Canada, 3SkinWise Dermatology, Manitoba, Canada, Manitoba, Canada, 4Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA, Nashville, TN, 5Johnson & Johnson, Horsham, PA, USA, Horsham, PA, 6Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, 7Johnson & Johnson, Horsham, PA, USA, Horsham, 8Janssen Inc, Toronto, ON, Canada, Toronto, Canada, 9Total Skin & Beauty Dermatology Center, Birmingham, AL, USA, Birmingham, 10Probity Medical Research, ON, Canada; University of Toronto, ON, Canada, Toronto, Canada, 11CCA Medical Research, ON, Canada, Toronto, Canada

Meeting: ACR Convergence 2025

Keywords: , , , ,

Session Information

Date: Sunday, October 26, 2025

Title: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Even low body surface area (BSA) psoriasis can be extremely bothersome to patients and can have a significant impact on their lives just as much as more extensive disease. SPECTREM is an ongoing, Phase 3b, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of guselkumab in participants with low BSA (2%-15%), moderate (Investigator’s Global Assessment [IGA]=3) psoriasis involving ≥1 special site (scalp, face, intertriginous, or genital).

Methods: A total of 338 participants were randomized 2:1 to receive guselkumab 100 mg (n=225) or placebo (n=113) at Week 0 and Week 4, then every 8 weeks. Patient-reported outcomes (PROs) assessed at Week 16 included change from baseline in Psoriasis Symptoms and Signs Diary (PSSD; range, 0-100), and Dermatology Life Quality Index (DLQI; range, 0-30).

Results: At baseline, participants had mean (standard deviation [SD]) BSA of 7.6% (3.7%); mean (SD) PSSD total symptoms score of 53.8 (23.2), mean (SD) PSSD itch score of 6.8 (2.2), and a mean (SD) DLQI of 11.5 (6.7). On average, participants had a disease duration of 17 years, and the majority of participants had never received systemic therapy (86.3%). At Week 16, guselkumab-treated participants achieved significantly greater mean change from baseline in the PSSD total symptoms score (guselkumab –36.08 vs placebo 0.37; p < 0.001). Among participants with PSSD itch score ≥4 at baseline, a significantly greater proportion of guselkumab-treated participants achieved ≥4-point reduction at Week 16 (guselkumab 62.7% vs placebo 12.5%; p < 0.001). A significant proportion of guselkumab-treated participants with PSSD symptom score >0 achieved a PSSD symptom score of 0 at Week 16 (21.9% vs placebo 2.7%; p < 0.001). Similarly, a significantly greater proportion of guselkumab-treated participants achieved DLQI 0/1 (guselkumab 48.9% vs placebo 3.5%; p < 0.001) and DLQI 0 (guselkumab 28.4% vs placebo 3.5% p < 0.001) at Week 16. No new safety signals were identified.

Conclusion: In this low BSA, moderate psoriasis population, quality of life impact significantly improved after just 3 doses of guselkumab.

Disclosures: J. Soung: AbbVie, 5, 12, Personal fees, Dermavant, 5, Eli Lilly, 12, Non-financial support (manuscript preparation during the conduct of the study), Kyowa Kirin, 5, LEO Pharma, 5, 12, Personal fees, Pfizer, 5, 12, Personal fees, Regeneron, 5, Sanofi, 5, 12, Personal fees; V. Kelly: AbbVie, 12,, 1, 2, 6, Allakaos, 12,, 1, 2, 6, Amgen, 12,, 1, 2, 6, Appolo, 12,, 1, 2, 6, Aslan pharmaceuticals, 12,, 1, 2, 6, Bausch Health, 12,, 1, 2, 6, Cara, 12,, 1, 2, 6, ConCERT pharmaceuticals, 12,, 1, 2, 6, Eli Lilly, 12,, 1, 2, 6, Galderma, 12,, 1, 2, 6, GSK, 12,, 1, 2, 6, Horizon, 12,, 1, 2, 6, Incyte, 12,, 1, 2, 6, Inmagene, 12,, 1, 2, 6, Innovaderm, 12,, 1, 2, 6, Janssen, 12,, 1, 2, 6, L’Oréal, 12,, 1, 2, 6, Laroche-Posay, 12,, 1, 2, 6, LEO Pharma, 12,, 1, 2, 6, Nektar, 12,, 1, 2, 6, Novartis, 12,, 1, 2, 6, Numab, 12,, 1, 2, 6, Opsidio, 12,, 1, 2, 6, Pfizer, 12,, 1, 2, 6, RAPT, 12,, 1, 2, 6, Sanofi, 12,, 1, 2, 6, Sun pharma, 12,, 1, 2, 6, UCB, 12,, 1, 2, 6, Verasci, 12,, 1, 2, 6; M. Wiseman: AbbVie, 12,, 1, 2, 6, Amgen, 12,, 1, 2, 6, Arcutis, 12,, 1, 2, 6, Asana BioSciences, 12,, 1, 2, 6, AstraZeneca, 12,, 1, 2, 6, Bausch Health, 12,, 1, 2, 6, Bristol Myers Squibb, 12,, 1, 2, 6, Celgene, 12,, 1, 2, 6, Dermira, 12,, 1, 2, 6, Eli Lilly, 12,, 1, 2, 6, Galderma, 12,, 1, 2, 6, Glenmark, 12,, 1, 2, 6, Incyte, 12,, 1, 2, 6, Janssen, 12,, 1, 2, 6, La Roche-Posay, 12,, 1, 2, 6, LEO Pharma, 12,, 1, 2, 6, Novartis, 12,, 1, 2, 6, Pfizer, 12,, 1, 2, 6, PRCL Research, 12,, 1, 2, 6, Principia, 12,, 1, 2, 6, Regeneron, 12,, 1, 2, 6, Sanofi, 12,, 1, 2, 6, UCB, 12,, 1, 2, 6; A. Rodriguez: Arcutis, 1, 6, Dermavent, 1, 6, Eli Lilly, 1, 6, EPI Health, 1, 6, Janssen, 1, 6, LEO Pharma, 1, 6, Novartis, 1, 6, Sciton, 1, 6, Strathspey Crown, 11, Sun Pharma, 1, 6, UCB, 1, 6; T. Alkousakis: Johnson & Johnson, 3, 11; O. Choi: Johnson & Johnson, 3, 11; D. Chan: Johnson & Johnson, 3, 11; K. Rowland: Johnson & Johnson, 3, 11; L. Hou: Johnson & Johnson, 3, 11; J. Jeyarajah: Johnson & Johnson, 3, 11; N. Abbarin: Janssen Research & Development, 3; E. Skobelev: Johnson & Johnson, 3, 11; S. Ramji: Johnson & Johnson, 3, 11; J. Krell: AbbVie, 12, Support, Amgen, 12, Support, Bristol Myers Squibb, 12, Support, Eli Lilly, 12, Support, Janssen Biotech, 12, Support, Sun Pharma, 12, Support, UCB, 12, Support; M. Sauder: AbbVie, 2, Amgen, 2, Arcutis, 2, Bausch Health, 2, Boehringer Ingelheim, 2, Bristol Myers Squibb, 2, Eli Lilly Canada, 2, Fresenius Kabi Canada, 2, Galderma, 2, Incyte, 2, Janssen, 2, L’Oreal Canada, 2, LEO Pharma, 2, Merck, 2, Novartis, 2, Pfizer, 2, Pierre Fabre, 2, Sanofi, 2, Sun Pharma, 2, UCB Canada, 2; D. Adam: AbbVie, 12,, 1, 6, Actelion, 12,, 1, 6, Amgen, 12,, 1, 6, Arcutis, 12,, 1, 6, Bausch Health, 12,, 1, 6, Boehringer Ingelheim, 12,, 1, 6, Bristol Myers Squibb, 12,, 1, 6, Celgene, 12,, 1, 6, Coherus, 12,, 1, 6, Dermavant, 12,, 1, 6, Dermira, 12,, 1, 6, Eli Lilly, 12,, 1, 6, Galderma, 12,, 1, 6, Incyte, 12,, 1, 6, Janssen, 12,, 1, 6, LEO Pharma, 12,, 1, 6, Merck, 12,, 1, 6, Novartis, 12,, 1, 6, Pfizer, 12,, 1, 6, Regeneron, 12,, 1, 6, Sanofi Genzyme, 12,, 1, 6, Sun Pharma, 12,, 1, 6, UCB, 12,, 1, 6.

To cite this abstract in AMA style:

Soung J, Kelly V, Wiseman M, Rodriguez A, Alkousakis T, Choi O, Chan D, Rowland K, Hou L, Jeyarajah J, Abbarin N, Skobelev E, Ramji S, Krell J, Sauder M, Adam D. SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/spectrem-guselkumab-significantly-improves-patient-reported-outcomes-at-week-16-in-participants-with-low-body-surface-area-moderate-psoriasis-with-special-sites-involvement/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spectrem-guselkumab-significantly-improves-patient-reported-outcomes-at-week-16-in-participants-with-low-body-surface-area-moderate-psoriasis-with-special-sites-involvement/